• Climb Bio entered an at-the-market equity distribution agreement with Jefferies for up to USD 100 million of common stock.
• Jefferies will act as sales agent with up to 3% commission on shares sold.
• The prior ATM program with Oppenheimer was terminated effective June 11, 2026; no shares were sold under that program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-269567), on June 12, 2026, and is solely responsible for the information contained therein.